x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243327
| Product Information | |
|---|---|
| CAS No. | 1432445-15-2 |
| Formula | C19H21F3N2OS |
| Molecular Weight | 382.44 |
| SMILES | O=C(N1CCN(C2=CC=C(C(F)(F)F)C=C2)CC1)CCCC3=CC=CS3 |
| Target | Endogenous Metabolite |
| Product Description | NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to off-white |
| Purity | 99.38% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 6 months; -20°C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
